
Novocure (NVCR) Stock Forecast & Price Target
Novocure (NVCR) Analyst Ratings
Bulls say
NovoCure Ltd is positioned for significant revenue growth, driven by a study that may enable Glioblastoma patients to commence treatment 2-3 months earlier, potentially increasing revenue per patient by 20-30%. The company's expansion efforts in the United States and Germany are expected to lead to an increase in active patients throughout 2026, which serves as a critical indicator for future revenue growth trajectories. Additionally, new market entries are anticipated to start generating incremental revenue within the next 12-18 months, complementing existing patient and revenue growth drivers.
Bears say
NovoCure Ltd faces a challenging financial outlook, as a significant drop in EBITDA is anticipated due to slow revenue growth projected over the coming quarters. The expectation is that it may take until 2027 for EBITDA to reach breakeven levels, indicating prolonged financial strain. Given the reliance on revenue ramp-up and the uncertainty associated with achieving these milestones, the outlook for the company's financial performance remains negative.
This aggregate rating is based on analysts' research of Novocure and is not a guaranteed prediction by Public.com or investment advice.
Novocure (NVCR) Analyst Forecast & Price Prediction
Start investing in Novocure (NVCR)
Order type
Buy in
Order amount
Est. shares
0 shares